fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Model of the human nose reveals first steps of SARS-CoV-2 and RSV infection

Written by | 12 Mar 2022

Preclinical models that recapitulate aspects of human airway disease are essential for the advancement of novel therapeutics and vaccines. In the current study published in the journal mBIO, researchers… read more.

Does strep throat lead to the development of tics?

Written by | 7 Mar 2022

A new study has found no link between a strep throat infection and the development of tics in children who have a parent or sibling with a chronic… read more.

Sense of smell is our most rapid warning system

Written by | 30 Oct 2021

The ability to detect and react to the smell of a potential threat is a precondition of our and other mammals’ survival. Using a novel technique, researchers at… read more.

FDA approves Vaxneuvance (pneumococcal 15-valent conjugate vaccine) for the prevention of invasive pneumococcal disease in adults 18 years and older caused by 15 serotypes – Merck Inc.

Written by | 23 Jul 2021

Merck Inc., announced the FDA has approved Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes… read more.

SARS-CoV-2 infection starts in nasal ciliated cells

Written by | 10 Jul 2021

Journal of Clinical Investigation The discovery that multiciliated cells in the nasal epithelium are the first cells to be targeted in early COVID-19 infection might provide the rationale… read more.

CHMP recommends Xolair an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps.- Novartis

Written by | 27 Jun 2020

Novartis has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Xolair (omalizumab) as… read more.

Elocta gains increased access for people with haemophilia A in the UK.- SOBI

Written by | 27 Jun 2020

Through an agreement with National Health Service (NHS) and Sobi,( Swedish Orphan Biovitrium) people living with haemophilia A in the United Kingdom will have increased access to Elocta… read more.

Phase III SYNAPSE study of Nucala meets endpoints in chronic rhinosinusitis with nasal polyps.- GlaxoSmithKline

Written by | 4 Apr 2020

GlaxoSmithKline announced positive results from the pivotal phase III SYNAPSE study of Nucala (mepolizumab) in patients suffering from chronic rhinosinusitis with nasal polyps (CRSwNP). This is the first… read more.

Phase III ELIPSE HoFH trial results of REGN 1500 met primary endpoint in homozygous familial hypercholesterolemia.- Regeneron Pharma

Written by | 1 Apr 2020

Regeneron Pharmaceuticals announced that detailed Phase III ELIPSE HoFH trial results of REGN 1500 (evinacumab) in patients with homozygous familial hypercholesterolemia (HoFH). The data showed the trial met… read more.

Discovered interaction between bacteria and immune cells protects the intestinal barrier

Written by | 17 Nov 2019

The result opens new avenues for the treatment of disorders such as ulcerative colitis or Crohn’s disease.

Adults' tonsillectomy complications and pain are higher than previously thought

Written by | 2 May 2014

Twenty percent of adults who have tonsillectomies will have a complication, which is significantly higher than previously shown, according to a team of researchers. The team also found… read more.

Antibiotic Rx for acute rhinosinusitis

Written by | 27 May 2013

Antibiotics for acute rhinosinusitis (ARS) are prescribed frequently – especially for younger adult patients and in primary care settings – despite recent consensus guidelines that discourage antibiotic use… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.